Abstract
Abstract We have shown that in particular tumor cells at the invasive front undergo a partial epithelial-mesenchymal transition (EMT) and aberrantly express EMT-associated transcription factors (EMT-TFs). The amount of such cancer cells strongly correlates with metastasis formation and poor clinical outcome in human cancers. Strikingly, metastases show a mesenchymal-epithelial retransition (MET) with a redifferentiated phenotype, indicating high cancer cell plasticity and supporting a regulatory role of the tumor environment. We described that the EMT-TF ZEB1 is a crucial determinant of cellular plasticity. At the molecular level, ZEB1 is linked in a double-negative feedback loop with the miR-200 family and miR-203, which are strong inducers of epithelial differentiation. Thus, aberrant ZEB1 expression stabilizes EMT and stemness, thereby promoting dissemination, metastasis, and drug resistance of cancer cells. We have validated the findings by showing that a depletion of ZEB1 in the KPC-mouse model of pancreatic cancer counteracts tumor cell plasticity and metastasis. Moreover, we detected that ZEB1 controls the Notch pathway and directly cooperates with the Hippo-pathway effector YAP in driving aggressive cancer types. We determined epigenetic modifications conferred by ZEB1, and screened for epigenetic drug to restore expression of its silenced target genes and to subsequently overcome therapy resistance. Despite their potent tumor-promoting effects, EMT-TFs are rarely mutated in cancer. This likely is due to the necessity for a transient expression and the associated plasticity of cancer cells, underscoring the important role of nonmutated genes in cancer progression. Citation Format: Thomas Brabletz. Cellular plasticity in cancer: Driving force and therapeutic target [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr CN07-01.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
